ARTICLE SUMMARY:
FDA approved a record number of PMA and PMA supplements, and more data on FDA authorizations and global policymaking in 2025 in our latest Scorecard infographic.
The challenging year of firings and staff departures did not show up in FDA’s 2025 device authorization numbers, according to Market Pathways’ Scorecard analysis. Overall totals were on pare with past years, and 2025 turned out to be a record year for the combined number of original PMA and panel-track supplement approvals, which are the most data-heavy device applications.
China’s National Medical Products Administration was the most prolific global publisher of medtech policy documents last year, with FDA second on the list, as tracked by Market Pathways Document Depot.
